(firstQuint)A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide.

 This is an open-label, Phase 2 study that will investigate the incidence of diarrhea in HER2+ breast cancer patients receiving neratinib with intensive loperamide diarrhea prophylaxis, alone and in combination with an anti-inflammatory treatment or a bile acid sequestrant treatment, who have previously undergone a course of trastuzumab therapy in the adjuvant setting.

 Patients will receive: - Neratinib 240 mg orally once daily for thirteen (13) 28-day cycles.

 - Loperamide daily for two (2) 28-day cycles and then as needed.

 - Starting with Amendment 3, an anti-inflammatory treatment for 1 cycle and loperamide to be administered daily for two (2) 28-day cycles and then as needed, thereafter; - Starting with Amendment 4, colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter; - Starting with Amendment 5, colestipol for 1 cycle and loperamide to be administered on an as-needed basis only.

.

 A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide@highlight

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis